Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

  1. Fizazi, K.
  2. Retz, M.
  3. Petrylak, D.P.
  4. Goh, J.C.
  5. Perez-Gracia, J.
  6. Lacombe, L.
  7. Zschäbitz, S.
  8. Burotto, M.
  9. Mahammedi, H.
  10. Gravis, G.
  11. Bastos, D.A.
  12. McCune, S.L.
  13. Vázquez Limón, J.C.
  14. Kwan, E.M.
  15. Castellano, D.
  16. Fléchon, A.
  17. Saad, F.
  18. Grimm, M.-O.
  19. Shaffer, D.R.
  20. Armstrong, A.J.
  21. Bhagavatheeswaran, P.
  22. Amin, N.P.
  23. Ünsal-Kaçmaz, K.
  24. Wang, X.
  25. Li, J.
  26. Loehr, A.
  27. Pachynski, R.K.
  28. Erakutsi egile guztiak +
Aldizkaria:
Journal for immunotherapy of cancer

ISSN: 2051-1426

Argitalpen urtea: 2022

Alea: 10

Zenbakia: 8

Mota: Artikulua

DOI: 10.1136/JITC-2022-004761 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus